What is Ogen 1.25
Estrone sulfateThe Generic name of this drug
Treatment SummaryEstrone sulfate (as estropipate) is a form of estrogen hormone replacement therapy that can be used to treat menopause symptoms, certain types of infertility, underdevelopment of female sexual characteristics, vaginal atrophy, certain types of breast cancer (especially in men and postmenopausal women), prostate cancer, and osteoporosis.
Ogenis the brand name
Ogen 1.25 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ogen
Estrone sulfate
1977
21
Approved as Treatment by the FDA
Estrone sulfate, also known as Ogen, is approved by the FDA for 10 uses including moderate Menopausal Vasomotor Symptoms and moderate Vulvovaginal atrophy .moderate Menopausal Vasomotor Symptoms
moderate Vulvovaginal atrophy
hypoestrogenism
Low Testosterone
Postmenopausal Osteoporosis
Hot flashes
female castration
Menopause
severe menopausal vulvovaginal atrophy
Premature Menopause
Effectiveness
How Ogen 1.25 Affects PatientsEstropipate is a type of estrogen, which is a hormone naturally produced by the body. Estropipate works by attaching to receptors that respond to estrogen in the body and helps to regulate the hormones LH and FSH. This can help to lower their levels in postmenopausal women.
How Ogen 1.25 works in the bodyEstradiol is a hormone that acts on female organs, breasts, and other parts of the body. When it enters a cell, it binds to a receptor and enters the nucleus. This triggers the production of proteins that express the effects of estradiol on the cell. Estrogens also increase the production of certain proteins in the liver and decrease FSH production in the pituitary gland.
When to interrupt dosage
The proposed dosage of Ogen 1.25 is contingent upon the diagnosed circumstance, including Menopause, Menopause and hypoestrogenism. The quantity of dosage varies, in accordance with the delivery strategy (e.g. Oral or Tablet, coated) mentioned in the table below.Condition
Dosage
Administration
Menopause
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
Hot flashes
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
hypoestrogenism
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
female castration
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
Premature Menopause
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
Postmenopausal Osteoporosis
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
severe menopausal vulvovaginal atrophy
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
moderate Menopausal Vasomotor Symptoms
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
moderate Vulvovaginal atrophy
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
Low Testosterone
0.75 mg, , 1.25 mg, 1.5 mg, 3.0 mg, 0.625 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, coated, Tablet, Tablet - Oral, , Cream - Vaginal, Cream, Tablet, film coated, Tablet, film coated - Oral, Vaginal, Tablet, coated - Oral
Warnings
There are 20 known major drug interactions with Ogen 1.25.Common Ogen 1.25 Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Estrone sulfate.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Estrone sulfate.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Estrone sulfate.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Estrone sulfate.
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrone sulfate.
Ogen 1.25 Novel Uses: Which Conditions Have a Clinical Trial Featuring Ogen 1.25?
39 active clinical trials are presently investigating the potential of Ogen 1.25 in alleviating Low Testosterone, hypoestrogenism and moderate Menopausal Vasomotor Symptoms.Condition
Clinical Trials
Trial Phases
moderate Menopausal Vasomotor Symptoms
0 Actively Recruiting
Postmenopausal Osteoporosis
4 Actively Recruiting
Not Applicable, Phase 4, Phase 3
hypoestrogenism
1 Actively Recruiting
Phase 4
Low Testosterone
18 Actively Recruiting
Phase 1, Phase 2, Phase 4
Premature Menopause
0 Actively Recruiting
moderate Vulvovaginal atrophy
0 Actively Recruiting
Menopause
0 Actively Recruiting
Hot flashes
19 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1
severe menopausal vulvovaginal atrophy
0 Actively Recruiting
female castration
0 Actively Recruiting
Ogen 1.25 Reviews: What are patients saying about Ogen 1.25?
5Patient Review
4/12/2012 I started taking ogen 5 years after my hysterectomy, when I was 34. I think this drug could really help a lot of women who are struggling emotionally and physically after surgery.
5Patient Review
7/16/2010 I've been taking this drug for years with great results and no problems. I'm disappointed that it's no longer on the market. Can anyone explain why it was pulled?
5Patient Review
6/10/2010 I loved that this medication had no side effects for me, but I'm disappointed that it's been taken off the market.
5Patient Review
5/21/2009 I've been very pleased with the results of this treatment. I had surgery in 1990 and am wondering if I should continue taking it or not.
2Patient Review
12/15/2009 I saw more success when I was taking this drug alongside estratest hs. Now that I've stopped, I'm back to experiencing extreme vaginal dryness and painful sex. Can I go back to alternating the estratest every other day and ogen every day? Is there something better out there?
Patient Q&A Section about ogen 1.25
What does OGEN do?
"Ogen (estropipate) tablets are a prescription medication used to treat the symptoms of menopause, ovarian failure, and the prevention of osteoporosis. Ogen may be used alone or with other medications and belongs to a class of drugs called estrogen derivatives. The safety and effectiveness of Ogen in children is not yet known." - Anonymous Online Contributor
Unverified Answer
What does Premarin do to your body?
"Premarin is a type of hormone replacement therapy that helps to relieve the discomfort that many women feel during and after menopause. These symptoms include hot flashes, sweating, and vaginal dryness." - Anonymous Online Contributor
Unverified Answer
What is OGEN made of?
"10, FD&C Blue No 1 and FD&C Red No. 3; OGEN. 750 (red tablet): FD&C Red No. 40, D&C Red 33,Yellow No. 6 and Red No. 3.
OGEN also contains colloidal silicon dioxide, dibasic potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and tromethamine. The color ingredients for the yellow tablet are: D&C Yellow No. 10, FD&C Blue No 1 and FD&C Red No. 3; The color ingredients for the red tablet are: FD&C Red No. 40, D&C Red 33,Yellow No. 6 and Red No. 3." - Anonymous Online Contributor
Unverified Answer
Can you crush extended release tablets?
"There are some newer slow-release tablet formulations available that can be divided or halved." - Anonymous Online Contributor
Unverified Answer